Zoetis Past Earnings Performance

Past criteria checks 3/6

Zoetis has been growing earnings at an average annual rate of 15%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 8.9% per year. Zoetis's return on equity is 47.9%, and it has net margins of 26.2%.

Key information

15.0%

Earnings growth rate

15.6%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate8.9%
Return on equity47.9%
Net Margin26.2%
Next Earnings Update04 May 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Zoetis makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BUL:ZOE Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 228,0802,1142,009539
30 Sep 228,0072,0672,088529
30 Jun 227,9952,0902,091527
31 Mar 227,8912,0732,057512
31 Dec 217,7762,0372,001508
30 Sep 217,6161,9821,926503
30 Jun 217,4121,9091,841483
31 Mar 217,0121,7741,734474
31 Dec 206,6751,6381,713463
30 Sep 206,5421,6631,665462
30 Jun 206,3401,6171,637462
31 Mar 206,3391,6111,655462
31 Dec 196,2601,5001,636457
30 Sep 196,1501,4611,553450
30 Jun 196,0461,3751,529446
31 Mar 195,9141,3881,482437
31 Dec 185,8251,4281,482432
30 Sep 185,7211,1641,424417
30 Jun 185,5881,1151,386405
31 Mar 185,4429781,362389
31 Dec 175,3078641,325382
01 Oct 175,1249371,320380
02 Jul 175,0188781,325374
02 Apr 174,9578551,323376
31 Dec 164,8888211,316376
02 Oct 164,8856891,362375
03 Jul 164,8586391,374376

Quality Earnings: ZOE has high quality earnings.

Growing Profit Margin: ZOE's current net profit margins (26.2%) are lower than last year (26.2%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ZOE's earnings have grown by 15% per year over the past 5 years.

Accelerating Growth: ZOE's earnings growth over the past year (3.8%) is below its 5-year average (15% per year).

Earnings vs Industry: ZOE earnings growth over the past year (3.8%) exceeded the Pharmaceuticals industry 2.8%.


Return on Equity

High ROE: Whilst ZOE's Return on Equity (47.94%) is outstanding, this metric is skewed due to their high level of debt.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/05/02 19:11
End of Day Share Price 2023/02/03 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zoetis Inc. is covered by 43 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Ishan MajumdarBaptista Research
Balaji PrasadBarclays